Impact of Nonalcoholic Fatty Liver Disease on Arrhythmia Recurrence Following Atrial Fibrillation Ablation.
暂无分享,去创建一个
T. Cotter | W. Saliba | O. Wazni | M. Kanj | B. Griffin | W. Jaber | Daniel J. Cantillon | Divyang R Patel | E. Donnellan | A. Hussein | B. Baranowski | M. Elshazly | Bryan Wilner | A. Kochar
[1] T. Cotter,et al. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease , 2020 .
[2] T. Cotter,et al. Nonalcoholic fatty liver disease: impact on healthcare resource utilization, liver transplantation and mortality in a large, integrated healthcare system , 2020, Journal of Gastroenterology.
[3] T. Cotter,et al. NAFLD 2020: The State of the Disease. , 2020, Gastroenterology.
[4] P. Schauer,et al. Association between pre-ablation bariatric surgery and atrial fibrillation recurrence in morbidly obese patients undergoing atrial fibrillation ablation. , 2019, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[5] W. Saliba,et al. Association Between Pre-Ablation Glycemic Control and Outcomes Among Patients With Diabetes Undergoing Atrial Fibrillation Ablation. , 2019, JACC. Clinical electrophysiology.
[6] J. Brugada,et al. Impact of body mass index on the outcome of catheter ablation of atrial fibrillation , 2018, Heart.
[7] Chengfu Xu,et al. Nonalcoholic Fatty Liver Disease Is Associated with Increased Atrial Fibrillation Risk in an Elderly Chinese Population: A Cross-Sectional Study , 2018, BioMed research international.
[8] R. Mahajan,et al. PREVEntion and regReSsive Effect of weight-loss and risk factor modification on Atrial Fibrillation: the REVERSE-AF study , 2018, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[9] Michael Charlton,et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.
[10] R. Hultcrantz,et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. , 2017, Journal of hepatology.
[11] S. Ernst,et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary , 2017, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[12] J. B. Moore,et al. Efficacy of dietary and physical activity intervention in non-alcoholic fatty liver disease: a systematic review , 2017, Proceedings of the Nutrition Society.
[13] Z. Goodman,et al. Epidemiology and natural history of non-alcoholic fatty liver disease. , 2016, Metabolism: clinical and experimental.
[14] L. Henry,et al. Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.
[15] R. Stauber,et al. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: guidelines, clinical reality and health economic aspects , 2016, Diabetologia.
[16] H. Huikuri,et al. Non-Alcoholic Fatty Liver Disease as a Predictor of Atrial Fibrillation in Middle-Aged Population (OPERA Study) , 2015, PloS one.
[17] Christopher X. Wong,et al. Long-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort: A Long-Term Follow-Up Study (LEGACY). , 2015, Journal of the American College of Cardiology.
[18] A. Toor,et al. Total Body Weight Loss of ≥10 % Is Associated with Improved Hepatic Fibrosis in Patients with Nonalcoholic Steatohepatitis , 2015, Digestive Diseases and Sciences.
[19] R. Mahajan,et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. , 2014, Journal of the American College of Cardiology.
[20] Randall C. Thompson,et al. Association of coronary artery calcification with hepatic steatosis in asymptomatic individuals. , 2013, Mayo Clinic proceedings.
[21] C. Hung,et al. Influence of Non-Alcoholic Fatty Liver Disease on Autonomic Changes Evaluated by the Time Domain, Frequency Domain, and Symbolic Dynamics of Heart Rate Variability , 2013, PloS one.
[22] Sombat Treeprasertsuk,et al. NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients. , 2013, World journal of gastroenterology.
[23] L. Di Biase,et al. Reply: To PMID 22464257. , 2013, Journal of the American College of Cardiology.
[24] G. Musso,et al. Obstructive Sleep Apnea–Hypopnea Syndrome and Nonalcoholic Fatty Liver Disease: Emerging Evidence and Mechanisms , 2012, Seminars in Liver Disease.
[25] Michael J Ackerman,et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[26] K. Filion,et al. Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. , 2011, The American journal of cardiology.
[27] Chiadi E. Ndumele,et al. Hepatic Steatosis, Obesity, and the Metabolic Syndrome Are Independently and Additively Associated With Increased Systemic Inflammation , 2011, Arteriosclerosis, thrombosis, and vascular biology.
[28] Enzo Bonora,et al. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. , 2010, The New England journal of medicine.
[29] T. Therneau,et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD , 2007, Hepatology.
[30] S. Goland,et al. Cardiac Abnormalities as a New Manifestation of Nonalcoholic Fatty Liver Disease: Echocardiographic and Tissue Doppler Imaging Assessment , 2006, Journal of clinical gastroenterology.
[31] K. Batts,et al. Chronic hepatitis. An update on terminology and reporting. , 1995, The American journal of surgical pathology.
[32] D. Levy,et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. , 1994, JAMA.
[33] G. MacGowan,et al. Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease. , 2012, Journal of hepatology.
[34] C. Day,et al. Non-alcoholic fatty liver disease: the mist gradually clears. , 2008, Journal of hepatology.
[35] D. Parish,et al. Obesity and the risk of new-onset atrial fibrillation. , 2005, JAMA.